Cargando…
Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center
PURPOSE: Infections remain a major challenge in the treatment of acute myeloid leukemia (AML). Induction-related mortality reported in the literature is approximately < 5% in clinical trials. However, the real-world scenario is different, especially in developing countries, given the high inciden...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713585/ https://www.ncbi.nlm.nih.gov/pubmed/33156719 http://dx.doi.org/10.1200/GO.20.00240 |
_version_ | 1783618590276059136 |
---|---|
author | Jain, Hasmukh Rengaraj, Karthik Sharma, Vibhor Bonda, Avinash Chanana, Raajit Thorat, Jayashree Ronghe, Ashwini Biswas, Sanjay Nayak, Lingaraj Tembhare, Prashant Subramnian, Papagudi Shetty, Dhanalaxmi Patkar, Nikhil Bagal, Bhausaheb Sengar, Manju |
author_facet | Jain, Hasmukh Rengaraj, Karthik Sharma, Vibhor Bonda, Avinash Chanana, Raajit Thorat, Jayashree Ronghe, Ashwini Biswas, Sanjay Nayak, Lingaraj Tembhare, Prashant Subramnian, Papagudi Shetty, Dhanalaxmi Patkar, Nikhil Bagal, Bhausaheb Sengar, Manju |
author_sort | Jain, Hasmukh |
collection | PubMed |
description | PURPOSE: Infections remain a major challenge in the treatment of acute myeloid leukemia (AML). Induction-related mortality reported in the literature is approximately < 5% in clinical trials. However, the real-world scenario is different, especially in developing countries, given the high incidence of multidrug-resistant (MDR) organisms, high incidence of fungal pneumonia at baseline, and significant delay before initiation of chemotherapy. We aimed to look at contemporary infections and infection-related mortality and analyze the patterns of infections. MATERIALS AND METHODS: This retrospective study was conducted at a large tertiary care oncology center in India. Patients with newly diagnosed AML who were older than age 15 years, considered fit for intensive therapy, and treated in the general wards of the adult hematolymphoid unit from March 1, 2014, until December 31, 2015, were included. RESULTS: One hundred twenty-one patients were treated during the study period. The most common presenting complaint was fever (85%). The focus of infection at presentation was found in 63% of patients, with respiratory infection being the most common (47%). MDR organisms were isolated in 55% of patients during induction from various foci. Klebsiella pneumoniae was the most common blood culture isolate (42.9%). Fungal pneumonia was diagnosed in 55% of patients during induction despite antifungal prophylaxis. Treatment-related mortality was 10.7% in all phases, with an induction mortality rate of 7.4%. Complete remission was attained in 69% of patients. Of all patients who received induction chemotherapy, 74% completed all three consolidation cycles. The 121 patients were followed up for a median period of 53 months. Four-year event-free survival was 35.8%, and 4-year overall survival was 41.5%. CONCLUSION: Infections and infection-related mortality are major challenges during AML induction. Gram-negative MDR and fungal infections are particularly common in our region. |
format | Online Article Text |
id | pubmed-7713585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-77135852020-12-04 Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center Jain, Hasmukh Rengaraj, Karthik Sharma, Vibhor Bonda, Avinash Chanana, Raajit Thorat, Jayashree Ronghe, Ashwini Biswas, Sanjay Nayak, Lingaraj Tembhare, Prashant Subramnian, Papagudi Shetty, Dhanalaxmi Patkar, Nikhil Bagal, Bhausaheb Sengar, Manju JCO Glob Oncol ORIGINAL REPORTS PURPOSE: Infections remain a major challenge in the treatment of acute myeloid leukemia (AML). Induction-related mortality reported in the literature is approximately < 5% in clinical trials. However, the real-world scenario is different, especially in developing countries, given the high incidence of multidrug-resistant (MDR) organisms, high incidence of fungal pneumonia at baseline, and significant delay before initiation of chemotherapy. We aimed to look at contemporary infections and infection-related mortality and analyze the patterns of infections. MATERIALS AND METHODS: This retrospective study was conducted at a large tertiary care oncology center in India. Patients with newly diagnosed AML who were older than age 15 years, considered fit for intensive therapy, and treated in the general wards of the adult hematolymphoid unit from March 1, 2014, until December 31, 2015, were included. RESULTS: One hundred twenty-one patients were treated during the study period. The most common presenting complaint was fever (85%). The focus of infection at presentation was found in 63% of patients, with respiratory infection being the most common (47%). MDR organisms were isolated in 55% of patients during induction from various foci. Klebsiella pneumoniae was the most common blood culture isolate (42.9%). Fungal pneumonia was diagnosed in 55% of patients during induction despite antifungal prophylaxis. Treatment-related mortality was 10.7% in all phases, with an induction mortality rate of 7.4%. Complete remission was attained in 69% of patients. Of all patients who received induction chemotherapy, 74% completed all three consolidation cycles. The 121 patients were followed up for a median period of 53 months. Four-year event-free survival was 35.8%, and 4-year overall survival was 41.5%. CONCLUSION: Infections and infection-related mortality are major challenges during AML induction. Gram-negative MDR and fungal infections are particularly common in our region. American Society of Clinical Oncology 2020-11-06 /pmc/articles/PMC7713585/ /pubmed/33156719 http://dx.doi.org/10.1200/GO.20.00240 Text en © 2020 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | ORIGINAL REPORTS Jain, Hasmukh Rengaraj, Karthik Sharma, Vibhor Bonda, Avinash Chanana, Raajit Thorat, Jayashree Ronghe, Ashwini Biswas, Sanjay Nayak, Lingaraj Tembhare, Prashant Subramnian, Papagudi Shetty, Dhanalaxmi Patkar, Nikhil Bagal, Bhausaheb Sengar, Manju Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center |
title | Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center |
title_full | Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center |
title_fullStr | Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center |
title_full_unstemmed | Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center |
title_short | Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center |
title_sort | infection prevalence in adolescents and adults with acute myeloid leukemia treated in an indian tertiary care center |
topic | ORIGINAL REPORTS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713585/ https://www.ncbi.nlm.nih.gov/pubmed/33156719 http://dx.doi.org/10.1200/GO.20.00240 |
work_keys_str_mv | AT jainhasmukh infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT rengarajkarthik infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT sharmavibhor infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT bondaavinash infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT chananaraajit infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT thoratjayashree infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT rongheashwini infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT biswassanjay infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT nayaklingaraj infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT tembhareprashant infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT subramnianpapagudi infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT shettydhanalaxmi infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT patkarnikhil infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT bagalbhausaheb infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter AT sengarmanju infectionprevalenceinadolescentsandadultswithacutemyeloidleukemiatreatedinanindiantertiarycarecenter |